Annual EBITDA
-$54.98 M
+$12.11 M+18.05%
31 December 2023
Summary:
Oncology Institute annual earnings before interest, taxes, depreciation & amortization is currently -$54.98 million, with the most recent change of +$12.11 million (+18.05%) on 31 December 2023. During the last 3 years, it has fallen by -$43.69 million (-387.00%). TOIIW annual EBITDA is now -18003.09% below its all-time high of $307.11 thousand, reached on 31 December 2019.TOIIW EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$12.34 M
+$2.63 M+17.56%
30 September 2024
Summary:
Oncology Institute quarterly earnings before interest, taxes, depreciation & amortization is currently -$12.34 million, with the most recent change of +$2.63 million (+17.56%) on 30 September 2024. Over the past year, it has increased by +$32.00 thousand (+0.26%). TOIIW quarterly EBITDA is now -12435.00% below its all-time high of $100.00 thousand, reached on 31 March 2021.TOIIW Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$60.95 M
+$32.00 K+0.05%
30 September 2024
Summary:
Oncology Institute TTM earnings before interest, taxes, depreciation & amortization is currently -$60.95 million, with the most recent change of +$32.00 thousand (+0.05%) on 30 September 2024. Over the past year, it has dropped by -$20.73 million (-51.54%). TOIIW TTM EBITDA is now -4020.06% below its all-time high of -$1.48 million, reached on 30 September 2021.TOIIW TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TOIIW EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +18.1% | +0.3% | -51.5% |
| 3 y3 years | -387.0% | -884.4% | -4020.1% |
| 5 y5 years | - | - | - |
TOIIW EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -387.0% | +18.1% | -884.4% | +69.2% | -4020.1% | +35.0% |
| 5 y | 5 years | <-9999.0% | +18.1% | <-9999.0% | +69.2% | -4020.1% | +35.0% |
| alltime | all time | <-9999.0% | +18.1% | <-9999.0% | +69.2% | -4020.1% | +35.0% |
Oncology Institute EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$12.34 M(-17.6%) | -$60.95 M(-0.1%) |
| June 2024 | - | -$14.96 M(-8.8%) | -$60.99 M(+32.5%) |
| Mar 2024 | - | -$16.41 M(-4.8%) | -$46.02 M(+4.1%) |
| Dec 2023 | -$54.98 M(-18.1%) | -$17.24 M(+39.4%) | -$44.20 M(+9.9%) |
| Sept 2023 | - | -$12.37 M(-15.2%) | -$40.23 M(-37.2%) |
| Mar 2023 | - | -$14.59 M(+9.9%) | -$64.05 M(-4.5%) |
| Dec 2022 | -$67.09 M | -$13.27 M(-30.2%) | -$67.09 M(-28.5%) |
| Sept 2022 | - | -$19.00 M(+10.5%) | -$93.82 M(+23.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2022 | - | -$17.19 M(-2.5%) | -$76.07 M(+28.5%) |
| Mar 2022 | - | -$17.64 M(-55.9%) | -$59.21 M(+42.8%) |
| Dec 2021 | -$41.47 M(+267.3%) | -$39.99 M(+3091.7%) | -$41.47 M(+2703.1%) |
| Sept 2021 | - | -$1.25 M(+283.8%) | -$1.48 M(-42.1%) |
| June 2021 | - | -$326.47 K(-426.5%) | -$2.56 M(+14.6%) |
| Mar 2021 | - | $100.00 K(-104.3%) | -$2.23 M(-4.3%) |
| Dec 2020 | -$11.29 M(-3776.2%) | - | - |
| Sept 2020 | - | -$2.33 M | -$2.33 M |
| Dec 2019 | $307.11 K | - | - |
FAQ
- What is Oncology Institute annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Oncology Institute?
- What is Oncology Institute annual EBITDA year-on-year change?
- What is Oncology Institute quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Oncology Institute?
- What is Oncology Institute quarterly EBITDA year-on-year change?
- What is Oncology Institute TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Oncology Institute?
- What is Oncology Institute TTM EBITDA year-on-year change?
What is Oncology Institute annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of TOIIW is -$54.98 M
What is the all time high annual EBITDA for Oncology Institute?
Oncology Institute all-time high annual earnings before interest, taxes, depreciation & amortization is $307.11 K
What is Oncology Institute annual EBITDA year-on-year change?
Over the past year, TOIIW annual earnings before interest, taxes, depreciation & amortization has changed by +$12.11 M (+18.05%)
What is Oncology Institute quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of TOIIW is -$12.34 M
What is the all time high quarterly EBITDA for Oncology Institute?
Oncology Institute all-time high quarterly earnings before interest, taxes, depreciation & amortization is $100.00 K
What is Oncology Institute quarterly EBITDA year-on-year change?
Over the past year, TOIIW quarterly earnings before interest, taxes, depreciation & amortization has changed by +$32.00 K (+0.26%)
What is Oncology Institute TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of TOIIW is -$60.95 M
What is the all time high TTM EBITDA for Oncology Institute?
Oncology Institute all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.48 M
What is Oncology Institute TTM EBITDA year-on-year change?
Over the past year, TOIIW TTM earnings before interest, taxes, depreciation & amortization has changed by -$20.73 M (-51.54%)